MK-0787
Total Payments
$30,000
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $30,000 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $30,000 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| In vitro activity and in vivo determination of the pharmacodynamic exposures of a novel metallo-betalactamase inhibitor, MBLI, that leads to restoration of Imipenem activity against drug-resistant, Enterobacteriaceae. | Merck Sharp & Dohme Corporation | $30,000 | 0 |
Top Doctors Receiving Payments for MK-0787
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Madison, WI | $30,000 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $30,000
Product Information
- Type Drug
- Total Payments $30,000
- Total Doctors 0
- Transactions 1
About MK-0787
MK-0787 is a drug associated with $30,000 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2018. In 2018, $30,000 was paid across 1 transactions to 0 doctors.
The most common payment nature for MK-0787 is "Unspecified" ($30,000, 100.0% of total).
MK-0787 is associated with 1 research study, including "In vitro activity and in vivo determination of the pharmacodynamic exposures of a novel metallo-betalactamase inhibitor, MBLI, that leads to restoration of Imipenem activity against drug-resistant, Enterobacteriaceae." ($30,000).